Difference between revisions of "High-grade B-cell lymphoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]")
Line 12: Line 12:
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
=Relapsed or refractory, subsequent lines of therapy=
 
=Relapsed or refractory, subsequent lines of therapy=
 +
==Lisocabtagene maraleucel monotherapy {{#subobject:6e6u14|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:6nvha6|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://doi.org/10.1016/s0140-6736(20)31366-0 Abramson et al. 2020 (TRANSCEND NHL-001)]
 +
|2016-01-11 to 2019-07-05
 +
| style="background-color:#91cf61" |Phase 1 (RT)
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Immunotherapy====
 +
*[[Lisocabtagene maraleucel (Breyanzi)]] target dose of 100 x 10<sup>6</sup> CAR T cells IV once on day 0
 +
'''One course'''
 +
</div></div>
 +
===References===
 +
#'''TRANSCEND NHL-001:''' Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254):839-852. Epub 2020 Sep 1. [https://doi.org/10.1016/s0140-6736(20)31366-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/32888407/ PubMed] NCT02631044
 
==Loncastuximab tesirine monotherapy {{#subobject:jgua99|Regimen=1}}==
 
==Loncastuximab tesirine monotherapy {{#subobject:jgua99|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">

Revision as of 13:14, 2 June 2023

Back to Top

Section editor transclusions Note: High-grade B-cell lymphoma (HGBL) was not considered as a named entity until the 2016 revision of the WHO guidelines, and includes entities such as double-hit lymphoma and triple-hit lymphoma which were previously classified under diffuse large B-cell lymphoma. We will populate this page with relevant regimens over time.

7 regimens on this page
7 variants on this page


Relapsed or refractory, subsequent lines of therapy

Lisocabtagene maraleucel monotherapy

Regimen

Study Dates of enrollment Evidence
Abramson et al. 2020 (TRANSCEND NHL-001) 2016-01-11 to 2019-07-05 Phase 1 (RT)

Immunotherapy

One course

References

  1. TRANSCEND NHL-001: Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254):839-852. Epub 2020 Sep 1. link to original article contains dosing details in abstract PubMed NCT02631044

Loncastuximab tesirine monotherapy

Regimen

FDA-recommended dose
Study Dates of enrollment Evidence
Caimi et al. 2021 (LOTIS-2) 2018-2019 Phase 2 (RT)

Antibody-drug conjugate therapy

  • Loncastuximab tesirine (Zynlonta) as follows:
    • Cycles 1 & 2: 0.15 mg/kg IV over 30 minutes once on day 1
    • Cycle 3 onwards: 0.075 mg/kg IV over 30 minutes once on day 1

Supportive therapy

21-day cycles for up to 18 cycles (1 year)

References

  1. LOTIS-2: Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):790-800. Epub 2021 May 11. link to original article contains dosing details in abstract PubMed Clinical Trial Registry
Retrieved from "https://hemonc.org/w/index.php?title=High-grade_B-cell_lymphoma&oldid=71984"